Biomedical Engineering Reference
In-Depth Information
55. Nagasawa H, Fujiki A, Fujikura N et al (2002) Effects of a novel class III antiarrhythmic
agent, NIP-142, on canine atrial fibrillation and flutter. Circ J 66:185-191
56. Matsuda T, Ito M, Ishimaru S et al (2006) Blockade by NIP-142, an antiarrhythmic agent, of
carbachol-induced atrial action potential shortening and GIRK1/4 channel. J Pharmacol Sci
101:303-310
57. Matsuda T, Takeda K, Ito M et al (2005) Atria selective prolongation by NIP-142, an
antiarrhythmic agent, of refractory period and action potential duration in guinea pig
myocardium. J Pharmacol Sci 98:33-40
58. Finlay HJ, Lloyd J, Nyman M et al (2008) Pyrano-[2,3b]-pyridines as potassium channel
antagonists. Bioorg Med Chem Lett 18:2714-2718
59. Claremon DA, McIntyre CJ, Liverton NJ (2002) Preparation of isoquinolinone compounds
as potassium channel inhibitors, WO 2002024655, Merck & Co., Inc., USA, p 96
60. Dinsmore CJ, Bergman JM (2005) Preparation of quinoline potassium channel inhibitors,
WO 2005030792, Merck & Co., Inc., USA, p 64
61. Dinsmore CJ, Bergman JM, McIntyre CJ et al (2005) Preparation of isoquinolinone potas-
sium channel inhibitors, WO 2005046578, Merck & Co., Inc., USA, p 54
62. Dinsmore CJ, Bergman JM, McIntyre CJ et al (2005) Preparation of isoquinoline derivatives
as potassium channel inhibitors, WO 2005030726, Merck & Co., Inc., USA, p 56
63. Isaacs R, Dinsmore CJ, McIntyre CJ et al (2005) Preparation of isoquinoline derivatives
as potassium channel inhibitors, WO 2005030727, Merck & Co., Inc., USA, p 48
64. Isaacs R, Dinsmore CJ, Trotter BW et al (2005) Preparation of isoquinoline derivatives as
potassium channel inhibitors, WO 2005030729, Merck & Co., Inc., USA, p 114
65. Trotter BW, Claiborne C, Ponticello GS et al (2005) Preparation of isoquinoline derivatives
as potassium channel inhibitors, WO 2005030791, Merck & Co., Inc., USA, p 56
66. Trotter BW, Isaacs R (2005) Preparation of quinazoline potassium channel inhibitors, WO
2005030217, Merck & Co., Inc., USA, p 48
67. Trotter BW, Nanda KK, Kett NR et al (2005) Preparation of isoquinoline derivatives as
potassium channel inhibitors, WO 2005030130, Merck & Co., Inc., USA, p 115
68. Trotter BW, Nanda KK, Kett NR et al (2006) Design and synthesis of novel isoquinoline-
3-nitriles as orally bioavailable Kv1.5 antagonists for the treatment of atrial fibrillation.
J Med Chem 49:6954-6957
69. Fedida D, Eldstrom J, Hesketh JC et al (2003) Kv1.5 is an important component of
repolarizing K+ current in canine atrial myocytes. Circ Res 93:744-751
70. Brendel J, Schmidt W, Below P (2001) Preparation of 2
0
-aminomethylbiphenyl-
2-carboxamides as Kv1.5 potassium channel blockers, WO 2001025189, Aventis Pharma
Deutschland G.m.b.H., Germany, p 125
71. Peukert S, Brendel J, Pirard B et al (2003) Identification, synthesis, and activity of novel
blockers of the voltage-gated potassium channel Kv1.5. J Med Chem 46:486-498
72. de Haan S, Greiser M, Harks E et al (2006) AVE0118, blocker of the transient outward
current (I(to)) and ultrarapid delayed rectifier current (I(Kur)), fully restores atrial contrac-
tility after cardioversion of atrial fibrillation in the goat. Circulation 114:1234-1242
73. Gogelein H, Brendel J, Steinmeyer K et al (2004) Effects of the atrial antiarrhythmic drug
AVE0118 on cardiac ion channels. Naunyn Schmiedebergs Arch Pharmacol 370:183-192
74. Oros A, Volders PG, Beekman JD et al (2006) Atrial-specific drug AVE0118 is free of
torsades de pointes in anesthetized dogs with chronic complete atrioventricular block. Heart
Rhythm 3:1339-1345
75. Wirth KJ, Paehler T, Rosenstein B et al (2003) Atrial effects of the novel K(+)-channel-
blocker AVE0118 in anesthetized pigs. Cardiovasc Res 60:298-306
76. Blaauw Y, Gogelein H, Tieleman RG et al (2004) “Early” class III drugs for the treatment of
atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat.
Circulation 110:1717-1724
